Second Sight Medical Products (NASDAQ: EYES) and Trivascular Technologies (NASDAQ:TRIV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitabiliy, institutional ownership and earnings.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Second Sight Medical Products and Trivascular Technologies, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Second Sight Medical Products 0 0 1 0 3.00
Trivascular Technologies 0 0 0 0 N/A

Second Sight Medical Products presently has a consensus price target of $5.00, indicating a potential upside of 362.96%. Given Second Sight Medical Products’ higher possible upside, research analysts clearly believe Second Sight Medical Products is more favorable than Trivascular Technologies.

Insider & Institutional Ownership

15.6% of Second Sight Medical Products shares are owned by institutional investors. 34.7% of Second Sight Medical Products shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Second Sight Medical Products and Trivascular Technologies’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Second Sight Medical Products $5.14 million 11.84 -$34.36 million ($0.72) -1.50
Trivascular Technologies N/A N/A N/A N/A N/A

Trivascular Technologies has higher revenue, but lower earnings than Second Sight Medical Products.


This table compares Second Sight Medical Products and Trivascular Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Second Sight Medical Products -646.89% -168.49% -129.48%
Trivascular Technologies -143.61% -766.90% -66.97%


Second Sight Medical Products beats Trivascular Technologies on 6 of the 8 factors compared between the two stocks.

About Second Sight Medical Products

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.

About Trivascular Technologies

Trivascular Technologies, Inc. is a medical device company developing and commercializing technologies to advance minimally invasive treatment of abdominal aortic aneurysms (AAA). The Ovation System, the Company’s solution for the treatment of AAA through minimally invasive endovascular aortic repair, or EVAR, is a stent graft platform, providing an alternative to conventional devices. It is designed to specifically address many of the limitations associated with conventional EVAR devices and expand the pool of patients eligible for EVAR. The Company is developing Ovation iX iliac limbs for use with both its Ovation Prime and its Ovation iX and Alto aortic bodies, which are in development. Trivascular is developing Ovation iX aortic bodies for use with both its Ovation Prime and its Ovation iX iliac limbs. The Company is developing an aortic body that together with the iliac limbs makes up the Ovation Alto stent graft.

Receive News & Ratings for Second Sight Medical Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products Inc. and related companies with's FREE daily email newsletter.